Binds Drug, Hapten, Hapten-carrier Complex, Or Specifically-identified Chemical Structure (e.g., Theophylline, Digoxin, Etc.) Patents (Class 530/389.8)
-
Publication number: 20120178116Abstract: The invention relates to a combination of polypeptides from phytopathogenic fungi having the biological activity of an aurora kinase and the function of an aurora kinase activator, to nucleic acids coding therefore, to the use of the polypeptides and nucleic acids for identifying modulators of an aurora kinase, to processes for identifying such modulators and to the use of these modulators as fungicides.Type: ApplicationFiled: December 20, 2011Publication date: July 12, 2012Inventors: Christoph Andreas Braun, Peter Schreier, Klaus-Gunther Tietjen, Michael Edmund Beck, Amos Mattes, Jorg Nico Greul, Oliver Gutbrod, Sandra Tuckmantel, Daniel Raun
-
Publication number: 20120177659Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.Type: ApplicationFiled: December 29, 2011Publication date: July 12, 2012Applicant: CELERA CORPORATIONInventors: Steve RUBEN, Karen VAN ORDEN, Candy N. LEE, Tao HE, Mehdi MESRI, Elizabeth G. JOSELOFF, Paul MOORE, Katherine MCKINNON, Bruno DOMON
-
Publication number: 20120171701Abstract: A method for the identification of regulatory T cells based on the diminished abundance or even absence of the global gene regulator SATB1 in such regulatory T cells. In particular, the invention relates to a method utilizing ligands that specifically bind to SATB1 for identifying regulatory T cells which are cells showing a reduced binding to said ligand. Such method is suitable for quality determination of a regulatory T cell population. A kit or diagnostic composition for such method is also disclosed.Type: ApplicationFiled: April 6, 2010Publication date: July 5, 2012Applicant: BECTON, DICKINSON AND COMPANYInventors: Joachim Ludwig Schultze, Marc Daniel Beyer, Noel Warner, Robert Balderas
-
Publication number: 20120171114Abstract: The present invention relates to new antibodies capable of binding specifically to the human CD151 protein, especially monoclonal antibodies of murine origin, which are chimeric and humanised, and also to the amino acid and nucleic sequences coding for those antibodies. The invention also includes use of those antibodies as medicaments for the prophylactic and/or therapeutic treatment of cancers and in diagnostic methods or kits for diseases associated with overexpression of the CD151 protein. Finally, the invention includes products and/or compositions comprising such antibodies in association with antibodies and/or anti-cancer agents or conjugated with toxins and/or radioelements and their use in the prevention and/or treatment of certain cancers.Type: ApplicationFiled: November 29, 2011Publication date: July 5, 2012Inventor: Jean-François Haeuw
-
Publication number: 20120171224Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: ApplicationFiled: February 8, 2012Publication date: July 5, 2012Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kristen Viola
-
Publication number: 20120171120Abstract: The present invention relates to antibodies that bind blood brain barrier receptors (BBB-R) and methods of using the same.Type: ApplicationFiled: November 29, 2011Publication date: July 5, 2012Applicant: Genentech, Inc.Inventors: Mark Dennis, Ryan Jefferson Watts, Yunhua Joy Yu, Yin Zhang
-
Publication number: 20120165218Abstract: Methods and immunoassays for the determination of fatty acid synthase (FAS) expression in patients having or suspected of having a proliferative disorder, especially prostate cancer, are disclosed. The sensitive method and assay detect the level of expression of FAS in a biological sample using antibodies that are highly specific for FAS. The method and assay can be used to monitor the progression of cancer, and/or to predict the efficacy of certain treatments or the likelihood of recurrence of the cancer.Type: ApplicationFiled: August 26, 2010Publication date: June 28, 2012Applicant: Nuclea Biotechnologies, Inc.Inventor: Patrick J. Muraca
-
Publication number: 20120164662Abstract: Provided is a test method for the assessment of the necessity of renal biopsy in a subject to be tested, who is suspected of having a renal disease. Specifically provided are a test method for a renal disease, including using urinary podocalyxin and one or more additional markers in combination, and a test reagent for use in the test method and a test reagent kit for use in the test method. The present invention allows the discrimination of a poor prognosis group even for poor prognosis cases with no overt findings in a conventional test method, and thus allows the assessment of a renal disease, the assessment of the necessity of renal biopsy, prognostic prediction, and the like to be performed exactly.Type: ApplicationFiled: June 9, 2010Publication date: June 28, 2012Applicants: DENKA SEIKEN CO., LTD, JUNTENDO EDUCATIONAL FOUNDATION, NIIGATA UNIVERSITYInventors: Masanori Hara, Akihiko Saito, Yasuhiko Tomino, Katsuhiko Asanuma, Hiroyuki Kurosawa, Shinya Ogasawara, Yoshiaki Hirayama
-
Publication number: 20120164159Abstract: A fully humanised antibody having binding specificity to Toll-like Receptor 2 comprises a light chain and a heavy chain entirely comprised of amino acid sequence of human origin. The variable region of the light chain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:1, while the variable region of the heavy domain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:4. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular for the treatment of inflammatory and autoimmune diseases which are mediated by Toll-like Receptor 2 activation and signalling.Type: ApplicationFiled: July 6, 2010Publication date: June 28, 2012Applicant: OPSONA THERAPEUTICS LIMITEDInventor: Jerome Dellacasagrande
-
Publication number: 20120164158Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: ApplicationFiled: January 30, 2012Publication date: June 28, 2012Applicant: MERCK SHARP & DOHME CORP.Inventors: GENE KINNEY, WILLIAM R. STROHL, ZHIQIANG AN
-
Publication number: 20120164756Abstract: The invention describes a method for monitoring and detecting non-therapeutic, therapeutic and toxic concentrations of aspirin in individuals which uses the urinary salicylic acid to salicyluric acid ratio.Type: ApplicationFiled: June 9, 2010Publication date: June 28, 2012Applicant: RANDOX LABORATORIES LIMITEDInventors: Elouard Benchikh, Stephen Peter Fitzgerald, Philip Andrew Lowry, Paul John Innocenzi, Ivan Robert McConnell
-
Publication number: 20120164667Abstract: Provided is a test method for the detection of diabetic nephropathy at an early stage as compared to a conventional method. Specifically provided are: a test method for diabetic nephropathy, including detecting urinary podocalyxin; the test method, further including assessing diabetic nephropathy at least Stage I; a test reagent for use in the test method; and a test reagent kit for use in the test method. The present invention is based on a finding that urinary podocalyxin reflects the development and condition of diabetic nephropathy with high sensitivity at an early stage as compared to urinary albumin.Type: ApplicationFiled: June 9, 2010Publication date: June 28, 2012Applicants: DENKA SEIKEN CO., LTD., JUNTENDO EDUCATIONAL FOUNDATION, NIIGATA UNIVERSITYInventors: Masanori Hara, Akihiko Saito, Yasuhiko Tomino, Katsuhiko Asanuma, Hiroyuki Kurosawa, Shinya Ogasawara, Yoshiaki Hirayama
-
Publication number: 20120156220Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.Type: ApplicationFiled: November 21, 2011Publication date: June 21, 2012Applicant: Xencor, Inc.Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
-
Publication number: 20120156194Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.Type: ApplicationFiled: December 16, 2011Publication date: June 21, 2012Applicant: Genentech, Inc.Inventors: Joseph R. Arron, Richard W. Erickson, Michelle Freemer, Meredith Hazen, Guiquan Jia, John G. Matthews, Wendy Putnam, Heleen Scheerens, Yanan Zheng
-
Publication number: 20120148578Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.Type: ApplicationFiled: November 21, 2011Publication date: June 14, 2012Applicant: XENCOR, INC.Inventors: SEUNG YUP CHU, JOHN R. DESJARLAIS, SHER BAHADUR KARKI, GREGORY ALAN LAZAR, GREGORY L. MOORE, IGOR VOSTIAR
-
Publication number: 20120148607Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: ApplicationFiled: November 3, 2011Publication date: June 14, 2012Applicant: ARGEN-X B.V.Inventors: Anna HULTBERG, Michael SAUNDERS, Johannes DE HAARD, Els FESTJENS, Natalie DE JONGE, Paolo Michieli, Cristina Basilico, Torsten Dreier
-
Publication number: 20120149765Abstract: The invention relates to the utilization of a substance for diagnostic determination of sgk1 (serum and glucocorticoid dependent kinase 1) and to the utilization of an active agent in order to influence sgk1 for therapeutic treatment of diseases associated with disordered activity of the tissue factor and to a diagnostic kit related to such substances or such active agents.Type: ApplicationFiled: December 9, 2011Publication date: June 14, 2012Inventor: Florian Lang
-
Publication number: 20120148572Abstract: The present invention relates to the use of VEGF antagonists and a novel anti-?5?1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-?5?1 antibodies and methods of making and using them.Type: ApplicationFiled: May 20, 2011Publication date: June 14, 2012Applicant: Genentech, Inc.Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
-
Publication number: 20120142903Abstract: The present application is in the field of sialic acid chemistry, metabolism and antigenicity. More particularly, the present invention relates to the detection and analysis of the non-human sialic acid, N-glycolylneuraminic acid (Neu5Gc) in biological materials, such as food and clinical specimens. Such detection and analysis is facilitated by the use of Neu5Gc specific antibodies. The present invention also relates to the detection of antiNeu5Gc antibodies in clinical samples, as well as the production of anti-Neu5Gc specific antibodies.Type: ApplicationFiled: November 28, 2011Publication date: June 7, 2012Inventors: Ajit Varki, Pam Tangvoranuntakul, Nissi Varki, Elaine Muchmore
-
Publication number: 20120135426Abstract: The invention involves a method for measuring phosphorylation of proteins at specific sites and, as such, is an indicator of the protein kinase activity of enzymes capable of phosphorylating those sites. The method involves the in vitro or in vivo phosphorylation of a target protein at a specific serine, threonine or tyrosine residue, subjecting that protein (non-phosphorylated) to reaction mixture containing all reagents, including phosphokinase which allow the creation of a phosphorylated form of protein. The phosphorylated protein is measured by contacting it with an antibody specific for the phosphorylation site(s). The invention includes antibodies useful in practicing the methods of the invention. The invention particularly relates to all proteins modified by phosphorylation and dephosphorylation as illustrated by Tau, Rb and EGFR proteins and antibodies specific for the site of phosphorylation of the Tau, Rb or EGFR proteins.Type: ApplicationFiled: September 26, 2011Publication date: May 31, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Kevin J. Reagan, Erik Schaefer, Jimin Wang
-
Publication number: 20120135428Abstract: The present invention relates to a method for determining the progression of chronic kidney disease in a subject suspected of having chronic kidney disease, comprising of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.Type: ApplicationFiled: October 25, 2011Publication date: May 31, 2012Inventors: Florian Kronenberg, Barbara Kollerits, Danilo Fliser
-
Publication number: 20120135004Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).Type: ApplicationFiled: August 26, 2011Publication date: May 31, 2012Applicant: Gilead Biologics, Inc.Inventors: Scott McCauley, Maria Vaysberg
-
Publication number: 20120135422Abstract: Disclosed is a discussion of a method for producing anti-mammalian GPCR antibody and of the antibody itself. Anti-mammalian GPCR antibody is produced through immunization involving exposure of fish to full-length or truncated mammalian GPCR, and anti-mammalian GPCR antibody that can be obtained by this method is also discussed.Type: ApplicationFiled: March 24, 2010Publication date: May 31, 2012Applicant: MIE UNIVERSITYInventor: Yutaka Tamaru
-
Publication number: 20120128678Abstract: [Problem to be Solved] An object of the present invention is to provide novel means for the treatment and diagnosis of cancer. [Solution] The present inventors have obtained a monoclonal antibody against TMPRSS11E and found that this antibody binds to a native form of TMPRSS11E, and TMPRSS11E is highly expressed on the cell membranes of cancer cell lines in flow cytometry. This antibody exhibits antibody-dependent cell-mediated cytotoxicity activity (ADCC activity) and antitumor effect based on internalization activity and is promising as a therapeutic target. Moreover, this antibody has neutralization activity against protease activity and is also expected to have effect brought about by the inhibition of TMPRSS11E functions.Type: ApplicationFiled: April 15, 2010Publication date: May 24, 2012Applicants: Forerunner Pharma Research Co., Ltd., The University of TokyoInventors: Hiroyuki Aburatani, Shunpei Ishikawa, Kiyataka Nakano
-
Publication number: 20120121610Abstract: The present invention relates to an agent that is useful in the treatment of a cell proliferative disease or disorder, and an assay for identifying such an agent.Type: ApplicationFiled: June 10, 2010Publication date: May 17, 2012Inventors: Carl Smythe, Richard Beniston
-
Publication number: 20120121501Abstract: The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided.Type: ApplicationFiled: October 18, 2011Publication date: May 17, 2012Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventors: Erkki Ruoslahti, Kimmo Porkka, Sven Christian
-
Publication number: 20120124705Abstract: The invention provides isolated nucleic acid molecules which encode novel fatty acid desaturases and elongases from the organism Emiliana huxleyi. The invention also provides recombinant expression vectors containing desaturase or elongase nucleic acid molecules, host cells into which the expression vectors have been introduced, and methods for large-scale production of long chain polyunsaturated fatty acids (LCPUFAs), e.g. arachidonic acid (ARA), eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA).Type: ApplicationFiled: July 15, 2010Publication date: May 17, 2012Applicant: BASF Plant Science Company GMBHInventors: Jörg Bauer, Johnathan A. Napier, Olga Sayanova
-
Publication number: 20120122726Abstract: The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.Type: ApplicationFiled: July 23, 2010Publication date: May 17, 2012Inventors: Miguel Abal Posada, Andreas Doll, Antonio Gil Moreno, Tamara Maes, Cristina Perez, Jaume Reventós Puigjaner, Elisabet Rossell
-
Publication number: 20120121609Abstract: The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (EGFR)-1(IIIb), EGFR-1(IIIc), and/or EGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing EGFR-1 or EGFR-4 as a treatment for obesity, diabetes, or a condition related thereto, and methods of reducing food intake.Type: ApplicationFiled: December 16, 2011Publication date: May 17, 2012Applicant: IMCLONE LLCInventors: Haijun SUN, Juqun SHEN, James R. TONRA
-
Publication number: 20120116059Abstract: The present invention relates to methods for the treatment and/or prophylaxis of multiple sclerosis (MS). Antagonists of GM-CSF, such as antibodies specific for GM-CSF or the GM-CSF receptor, are effective in the treatment and/or prophylaxis of multiple sclerosis.Type: ApplicationFiled: May 4, 2010Publication date: May 10, 2012Applicant: MORPHOSYS AGInventors: Stefan Steidl, Manuela Duerr, Elisabeth Thomassen-Wolf, Matthew Downham, Robert Friesen
-
Publication number: 20120114665Abstract: Isolated human antibodies or antigen-binding fragments thereof, which specifically bind to human RANKL and block hRANKL binding to a RANK receptor, are provided. The antibodies are useful in preventing or treating disorders and/or diseases, which are associated with RANKL/RANK interactions, including bone disorders or cancer.Type: ApplicationFiled: August 19, 2009Publication date: May 10, 2012Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Joel H. Martin, Aris N. Economides, Regina Raz
-
Publication number: 20120114666Abstract: The invention relates to a method of diagnosing an autoimmune neurological disorder in a mammal comprising the step of detecting, in a bodily fluid sample from the mammal, autoantibodies to an epitope of at least one Kv1-complex protein; and related methods, assay kits, isolated or purified autoantibody or antibody fragments, or uses thereof.Type: ApplicationFiled: October 26, 2009Publication date: May 10, 2012Applicant: ISIS INNOVATION LIMITEDInventor: Angela Vincent
-
Publication number: 20120115169Abstract: Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol.Type: ApplicationFiled: November 9, 2010Publication date: May 10, 2012Applicant: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.Inventors: Michael C. Mullenix, Robert Elliot Zipkin, Jeffrey Kroll Adams, Wayne Forrest Patton, James J. Donegan
-
Publication number: 20120114659Abstract: Monoclonal antibodies that act as potentiators, stimulators and agonists of guanylyl cyclase receptors are disclosed.Type: ApplicationFiled: November 17, 2009Publication date: May 10, 2012Applicants: MORPHOSYS AG, BOEHRINGER INGELHEIM PHARMACEUTICALS INC.Inventors: Alisa Waterman, Daniel Rajotte, Tobias Litzenburger, Alexandra Kraus
-
Publication number: 20120115830Abstract: Disclosed are methods that employ FKBPL as a marker for a subject's sensitivity to endocrine therapies in the treatment of cancers, and as a predictive marker of cancer progression and disease free survival in relation to hormone responsive cancers.Type: ApplicationFiled: May 19, 2010Publication date: May 10, 2012Inventors: Tracy Robson, David Hirst, Hayley McKeen, Christopher Byrne
-
Publication number: 20120115247Abstract: A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided.Type: ApplicationFiled: November 7, 2011Publication date: May 10, 2012Inventors: Patrick Albientz, Jean-Michel Grenet, Rainer Hillenbrand, Francois Legay, Peter Marbach, Séverine Marrony, Judith Schaefer
-
Publication number: 20120114671Abstract: The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. The invention also relates to a method for the identification of compounds capable of blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of subjects suffering from said tumors.Type: ApplicationFiled: April 6, 2010Publication date: May 10, 2012Applicants: FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA), FUNDACIO PRIVADA INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL HEBRON (IR-HUVH), FUNDACIO PRIVADA INSTITUT D'INVESTIGATIÓ ONCOLÒGICA VALL D'HEBRON (VHIO)Inventors: Joan Seoane Suarez, Silvia Penuelas Prieto, José Baselga Torres
-
Publication number: 20120108662Abstract: The present application relates to compositions and the treatment of skin disorders, dry skin, protection of skin in inflammatory events and neurological disorders. The present application more particularly discloses the identification of new genes and metabolic pathways involved in skin disorders, which provide novel targets and approaches for treating said disorders and for screening biologically active compounds. The present invention also provides various products and constructs, such as probes, primers, vectors, recombinant cells, which can be used to implement the above methods. The invention may be used to detect or treat various skin disorders, particularly dry and inflammatory skin disorders and neurological disorders, in various subjects, including mammalian subjects, particularly human beings.Type: ApplicationFiled: November 3, 2006Publication date: May 3, 2012Inventor: Judith Fischer
-
Publication number: 20120109097Abstract: The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.Type: ApplicationFiled: January 14, 2011Publication date: May 3, 2012Applicant: MEDIMMUNE, LLCInventors: Jennifer Lynne Reed, Herren Wu, Ying Tang, Julian Davies, Jeffry D. Watkins
-
Patent number: 8168756Abstract: Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.Type: GrantFiled: October 22, 2009Date of Patent: May 1, 2012Assignee: ARK Diagnostics, Inc.Inventors: Johnny Jose Valdez, Byung Sook Moon, Ki Chung, Alejandro A. Orozco
-
Publication number: 20120100158Abstract: A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.Type: ApplicationFiled: April 29, 2010Publication date: April 26, 2012Applicant: RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Gal Markel, Rona Ortenberg
-
Publication number: 20120094860Abstract: Methods for preparing an antibody are provided with the method including incorporating 3-bromo-4-hydroxy-benzoic acid into a protein to form an antigen, immunizing a mammalian host with the antigen, and recovering an antibody having an affinity for the antigen from the host. Antibodies having a binding affinity for a monohalotyrosine are provided as well as composition comprising an antibody bound with monohalotyrosine. Compositions comprising a protein having a 3-bromo-4-hydroxy-benzoic acid moiety are also provided. Methods for evaluating the severity of asthma are provide with the methods including analyzing sputum of a patient using an antibody having a binding affinity for monohalotyrosine, and measuring the amount of antibody bound to protein.Type: ApplicationFiled: October 19, 2011Publication date: April 19, 2012Inventors: Hongjun Jin, Richard C. Zangar
-
Publication number: 20120093837Abstract: The invention discloses binding agents to the E746-A750 deletion and the L858R point mutations in the epidermal growth factor receptor (EGFR) molecule, and methods for use thereof, including methods for the diagnosis and treatment of cancer.Type: ApplicationFiled: April 10, 2009Publication date: April 19, 2012Inventors: Ting-Lei Gu, Jiong Wu, Susan Kane, Jian Yu, Herbert Haack, James Wieler, Jun-Ming Cai, Victoria Rimkunas
-
Publication number: 20120094316Abstract: The invention relates to an immunoassay method and kit for the detection and/or the determination of mephedrone, mephedrone metabolites and related compounds. The invention is underpinned by a novel antibody, derived from a novel immunogen, that is sensitive and binds to mephedrone, mephedrone metabolites and related compounds.Type: ApplicationFiled: October 18, 2011Publication date: April 19, 2012Inventors: Robert Ivan McConnell, Elouard Benchikh, Philip Andrew Lowry, Stephen Peter Fitzgerald
-
Publication number: 20120088312Abstract: Novel conjugates and immunogens derived from vincristine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of vincristine in biological fluids.Type: ApplicationFiled: October 8, 2010Publication date: April 12, 2012Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Daniel J. Cline
-
Publication number: 20120088722Abstract: The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent activation of transforming growth factor beta (TGF?). The compounds are preferably polypeptide fragments of the hemopexin-like domain of the MMP, but may be mimetics thereof or peptides or mimetics of the portion of the MMP substrate protein to which the MMP interacts.Type: ApplicationFiled: October 7, 2011Publication date: April 12, 2012Inventors: Marina D'Angelo, Abdulhafez Selim
-
Publication number: 20120082680Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: September 23, 2011Publication date: April 5, 2012Applicant: Merck Sharp & Dohme Corp.Inventors: Ayesha Sitlani, Carl P. Sparrow, Shilpa Pandit, Jon H. Condra, Dana D. Wood, Timothy S. Fisher
-
Publication number: 20120082679Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: September 23, 2011Publication date: April 5, 2012Applicant: Merck Sharp & Dohme Corp.Inventors: Carl P. Sparrow, Ayesha Sitlani, Shilpa Pandit, Jon H. Condra, Holly A. Hammond
-
Publication number: 20120083589Abstract: The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.Type: ApplicationFiled: August 10, 2011Publication date: April 5, 2012Applicant: DINONA INC.Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Youngmee Bae, Seong-Pyo Park, Yoon-Kyung Jeon
-
Publication number: 20120082684Abstract: The present invention provides methods for diagnosing cell proliferation and/or differentiation disorders, compounds and methods for treating the same and methods for identifying agents potentially useful in the treatment of cell proliferation and/or differentiation disorders.Type: ApplicationFiled: March 15, 2010Publication date: April 5, 2012Applicant: UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEEInventors: Sonia Rocha, Angus Iain Lamond, Motoharu Ono, Kayo Yamada